Trial readouts
Trial readouts: 8 articles from Peptides Facts. Evidence-led reference on research peptides.
Mazdutide GLORY-1: Approved in One Country Only
A glucagon and GLP-1 receptor dual agonist with an oxyntomodulin lineage reached registration on a phase 3 trial run entirely in China. What GLORY-1 measured, and what a single-region population does to the evidence.
OASIS 4: The First Oral GLP-1 Approved for Obesity
A 307-participant registration trial converted an absorption-enhancer formulation into an approved product. Two effect figures circulate for the same trial, and the difference between them is an estimand, not an error.
SYNCHRONIZE-1: Survodutide's First Phase 3 Readout
The phase 2 programme left open whether glucagon-receptor agonism would show up anywhere other than the scale. The first phase 3 trial ran for 76 weeks, carried a prespecified imaging substudy, and reported two sets of numbers from two estimands.
Bimagrumab and the Lean-Mass Question: BELIEVE, and the Trial Lilly Stopped
Bimagrumab is an antibody, not a peptide. It belongs in this cluster because of the question incretin therapy raised: how much of the mass lost is not fat, and whether that proportion can be changed.
CagriSema and REDEFINE: What Adding Amylin Agonism Bought Over Semaglutide Alone
The phase 3 programme answered the question the combination was built to test, and then a harder one: how it compares with tirzepatide. Both answers are smaller than the phase 2 data implied.
Orforglipron: The First Non-Peptide GLP-1 Agonist, and Why It Is Not a Peptide Story
A small organic molecule reaches the same receptor as the incretin peptides by a different route, needs no absorption enhancer, and carries no fasting conditions. Its approval is a pharmacology story more than a peptide one.
Retatrutide TRIUMPH-1: What a 2,339-Person Phase 3 Actually Established
An 80-week phase 3 trial, read with both estimands, the discontinuation table, and the most quoted figure put back in its place. What TRIUMPH-1 settled about body-weight change, and what it left open.
EVOKE and EVOKE+: Why Semaglutide Did Not Slow Early Alzheimer's, and What the Biomarkers Showed
Two phase 3 trials enrolling 3,808 people found no difference from placebo on the clinical endpoint at two years. Small biomarker shifts in spinal fluid are the part of the result most likely to be misread.